Bicycle Therapeutics (BCYC) Cash & Equivalents (2018 - 2026)

Bicycle Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $559.5 million for Q1 2026.

• Quarterly Cash & Equivalents fell 29.45% year-over-year to $559.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $559.5 million (down 29.45% YoY) and the FY2025 annual result came in at $628.1 million, down 5.53% from the prior year.
• Cash & Equivalents was $559.5 million for Q1 2026 at Bicycle Therapeutics, down from $628.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $961.4 million in Q2 2024 and bottomed at $100.0 million in Q1 2022.
• A 5-year average of $543.0 million and a median of $559.5 million in 2026 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 48.95% — and 2023, when it surged 193.81%.
• Bicycle Therapeutics' Cash & Equivalents stood at $339.2 million in 2022, then surged by 55.22% to $526.4 million in 2023, then rose by 26.31% to $664.9 million in 2024, then dropped by 5.53% to $628.1 million in 2025, then decreased by 10.93% to $559.5 million in 2026.
• Business Quant data shows BCYC's Cash & Equivalents at $559.5 million in Q1 2026, $628.1 million in Q4 2025, and $648.3 million in Q3 2025.